+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effects of vicadrostat combined with empagliflozin in adults who have type 2 diabetes, high blood pressure, and established cardiovascular disease but no history of heart failure. This study aims to understand if this combination can reduce the risk of cardiovascular events compared to a placebo combined with empagliflozin. Participation is randomized and double-blinded to compare these treatments fairly. Participants are randomly assigned to one of two groups one takes vicadrostat plus empagliflozin, and the other takes placebo tablets that look like vicadrostat plus empagliflozin. They take one tablet daily for a period ranging from two and a half years up to four years and three months. All participants continue their regular medications for diabetes, hypertension, and cardiovascular disease alongside the study treatments. Throughout the study, participants attend regular visits where their health is carefully monitored. Doctors collect information about cardiovascular events and take blood samples. They also track any side effects and changes in blood pressure and kidney function. The main outcome is the time until the first cardiovascular death or heart failure event, observed over up to 51 months. Participants stay in the study for up to four years and three months with ongoing health assessments.

Age: 18Years +All GendersPhase 3
1142 locations
P

Actively Recruiting

Researchers are evaluating ADX-038, a drug delivered as siRNA duplex oligonucleotides, in adults with complement-mediated kidney diseases including IgA Nephropathy IgAN, C3 Glomerulopathy C3G, and Immune Complex-Mediated Membranoproliferative Glomerulonephritis IC-MPGN. This Phase 2 study aims to assess the safety, effectiveness, pharmacokinetics, and pharmacodynamics of ADX-038 in these patients. The study is sponsored by ADARx Pharmaceuticals, Inc. Participants receive one of several doses of ADX-038, categorized as Dose Level 1 or Dose Level 2, targeting different complement-mediated kidney conditions. The study follows a parallel design without randomization or masking. Treatment is administered over a period of up to 36 months, allowing researchers to observe long-term effects and safety. During the trial, participants will be monitored regularly to evaluate safety and tolerability, which is the primary outcome measure tracked for up to 36 months. Clinical evaluations, laboratory tests, and pharmacokinetic and pharmacodynamic assessments will be conducted to gather comprehensive data. Participants are expected to continue supportive care treatments, including ACE inhibitors or ARBs if applicable, and will receive necessary vaccinations as part of the study protocol.

Age: 18Years +All GendersPhase 2
38 locations
S

Actively Recruiting

This research aims to evaluate the effectiveness and safety of LUPKYNIS combined with belimumab, obinutuzumab, or anifrolumab in adults with lupus nephritis LN. The study focuses on how well these combinations induce a rapid kidney response in patients diagnosed with LN, a condition affecting kidney health. It is a phase 4 clinical trial sponsored by Aurinia Pharmaceuticals Inc. that assesses treatment approaches for this condition. Participants will receive LUPKYNIS along with one of the biologic agents belimumab, obinutuzumab, or anifrolumab. In addition, all patients will be treated with a mycophenolic acid analog MPAA, such as mycophenolate mofetil or mycophenolic acid, and corticosteroids like prednisone or an equivalent. The biologic treatment schedules vary depending on the specific drug, with some patients already receiving treatment before the study starts or beginning it at the start of the trial. During the study, participants will be monitored for kidney response over 24 weeks, including complete and partial renal responses. Researchers will assess safety by tracking treatment-emergent adverse events up to 28 weeks. Other assessments include measuring changes in kidney-related antibodies and complement levels at baseline, 12 weeks, and 24 weeks. The total participation duration extends to about 28 weeks, during which various evaluations, laboratory tests, and safety monitoring will occur to understand treatment effects and patient outcomes.

Age: 18Years - 75YearsAll GendersPhase 4
27 locations
P

Actively Recruiting

Researchers are evaluating the safety and tolerability of BHV-1400 as a treatment for people with IgA Nephropathy, a kidney condition confirmed by biopsy. This Phase 1 study aims to observe how participants respond to BHV-1400, an investigational drug administered under medical supervision. Participants will receive BHV-1400 through subcutaneous injections. This open-label study involves a single group receiving the study drug without a placebo comparison. The treatment period and dosing schedule are designed to monitor safety outcomes over a year. During the study, participants will be closely monitored for serious adverse events, adverse events leading to discontinuation, and deaths, along with laboratory abnormalities of grade 3 or 4 severity. The study lasts up to one year and includes regular evaluations to ensure participant safety and gather detailed safety data.

Age: 18Years - 65YearsAll GendersPhase 1
15 locations
S

Actively Recruiting

Researchers are studying the safety, effectiveness, and how the body processes the investigational drug WAL0921 in adults with various glomerular kidney diseases and proteinuria. These include diabetic nephropathy and rare conditions such as primary focal segmental glomerulosclerosis, treatment-resistant minimal change disease, primary immunoglobulin A nephropathy, and primary membranous nephropathy. This is a Phase 2, randomized, double-blind, placebo-controlled study conducted at multiple centers to evaluate WAL0921 compared to a placebo. Participants will be randomly assigned to receive either the investigational drug WAL0921 or a placebo through an intravenous infusion every two weeks for a total of seven infusions. The study includes a treatment period followed by a 24-week follow-up after the last infusion to monitor participants. The treatments are given in parallel groups to compare their effects and safety. During the study, participants will undergo regular assessments including monitoring for adverse events from the start through Week 36. Researchers will also measure changes in albuminuria, proteinuria, and kidney function markers such as estimated glomerular filtration rate over 24 weeks. These evaluations help determine how the drug affects kidney disease markers and overall safety. The total participation time includes treatment and follow-up periods lasting several months.

Age: 18Years - 75YearsAll GendersPhase 2
50 locations